<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00228930</url>
  </required_header>
  <id_info>
    <org_study_id>0208-14</org_study_id>
    <secondary_id>U01GM061373-05</secondary_id>
    <nct_id>NCT00228930</nct_id>
  </id_info>
  <brief_title>Tamoxifen Pharmacogenetics and Clinical Effects</brief_title>
  <official_title>A Pilot Trial Correlating Metabolic Profile of Tamoxifen With Pharmacogenetic Predictors and Clinical Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of General Medical Sciences (NIGMS)</source>
  <brief_summary>
    <textblock>
      The purpose of this research is to try to identify which women who take tamoxifen are likely
      to suffer from hot flashes or are more likely to have other side effects or benefits from the
      drug. The researchers will do so by determining whether there are mutations that normally
      occur in human DNA that might influence the way individuals respond to medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test the following hypotheses.

        1. There is a relationship between genetically distinct metabolic profiles of tamoxifen and
           the frequency and severity of hot flashes in women on chronic tamoxifen therapy.

        2. Genetically distinct metabolic profiles for tamoxifen effect lipid profile, bone
           turnover metabolites and bone mineral density, and coagulation factors.

        3. Different genetic profiles of estrogen responsive genes influence the pharmacodynamic
           effects of tamoxifen in cardiovascular system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">297</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen (pharmacodynamic analysis)</intervention_name>
    <description>Tamoxifen 20mg po daily</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood Serum Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients included women 18 years or older, non-pregnant or lactating, who were
        recommended tamoxifen for adjuvant treatment or for the prevention of breast cancer from
        the oncology clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-years or older

          2. Women with a prior breast cancer or who are at a high risk for developing the disease
             and about to start tamoxifen therapy.

          3. Participants must not be treated with concomitant chemotherapy or hormone therapy
             other than tamoxifen. They must not have ovarian ablation or currently being treated
             with radiation therapy and/or chronic corticosteroids.

          4. The participant must not be taking anti-hot flash therapy (clonidine, bellergal,
             megestrol acetate). Vitamin E, selective serotonin reuptake inhibitors, or herbal
             remedies are allowed provided that the participant has been taking the remedy for at
             least 4 weeks and intends to continue the remedy for at least the first month while on
             the study, and allows for one-month follow up evaluation (hot flash diaries and blood
             samples).

          5. The participant must not be pregnant or lactating.

          6. The participant is able and willing to sign an informed consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Flockhart, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCCC</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://medicine.iupui.edu/clinpharm</url>
    <description>The Division of Clinical Pharmacology, Indiana University</description>
  </link>
  <link>
    <url>http://www.pharmgkb.org</url>
    <description>The Pharmacogenetics and Pharmacogenomics Knowledge Base</description>
  </link>
  <link>
    <url>http://medicine.iupui.edu</url>
    <description>Drug Interactions--Cytochrome P450</description>
  </link>
  <results_reference>
    <citation>Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA. CYP2D6 genotype and tamoxifen response. Breast Cancer Res. 2005 Jul 29;7(5):E6.</citation>
    <PMID>16168100</PMID>
  </results_reference>
  <results_reference>
    <citation>Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005 May;55(5):471-8. Epub 2005 Feb 1.</citation>
    <PMID>15685451</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.</citation>
    <PMID>15632378</PMID>
  </results_reference>
  <results_reference>
    <citation>Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.</citation>
    <PMID>14652237</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):245-53.</citation>
    <PMID>12798184</PMID>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <keyword>Breast Cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Prevention</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

